Boy management sucks even worse than I thought. In a market of 25k plus ALS patients for which there are no competing therapies MTPA after 4 years in the market place has only 4% of patients on therapy today. Having peaked at 240m in 2018 (first full year) and fallen off by 54% in just 2.5 years. Further proof that you morons (in management ie JS) don’t know anything about how to market in rare disease. 4.5 calls a day! Idiots
From 240m in 2018 to 130m in 2020
- Thread starter anonymous
- Start date
-
- Tags
- None
And it’s your only product! Bahahaha how long until Japan realizes it was you idiots who killed the company and the product out of arrogance and stupidity
Wait until formulation #3 of a tired drug gets added and right before your mouth goes numb, all you test is metal 
Bad decisions one after another and they won’t stop until there is nothing left
Bad decisions one after another and they won’t stop until there is nothing leftDown by at least a bif every day and new product can’t be given away. How long before we’re cut or eliminated entirely?